2. >>Legal & IP

Glenmark Reveals Total Bill After Settling All US Zetia Antitrust Claims

Purchasers Claim Settled Last Week; Two Remaining Now Resolved

 
• By Dean Rudge

Glenmark has reached into its wallet to resolve claims, without admitting fault or liability, that it conspired with Merck to delay unlawfully generic competition to the originator’s Zetia.

wooden gavel with usa dollar on desk. close up. toned image

Glenmark Pharmaceuticals has agreed to shell out an additional $39.5m to resolve all antitrust litigation centered around the Indian firm’s generic version of Merck & Co’s Zetia (ezetimibe) heart-disease blockbuster, ensuring Glenmark will not face a rare pay-for-delay jury trial.

A myriad of purchasers had brought antitrust claims against the pair, accusing them of striking an anticompetitive deal in 2010 that deprived the market of cheaper generic competition for almost five years, while also allowing for Glenmark to

More from Legal & IP

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By Dean Rudge

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

More from Generics Bulletin